secwatch.observer — SEC 8-K summary
======================================

Issuer:     IDEXX LABORATORIES INC /DE (IDXX)
CIK:        0000874716
Form:       8-K
Filed at:   2025-08-04T23:59:59+00:00
Accession:  0001104659-25-073304
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IDEXX Q2 EPS $3.63 (+49% reported); raises FY2025 revenue and EPS guidance
--------------------------------------------------------------------------

- Q2 revenue $1,109M (+11% reported, +9% organic); CAG Diagnostics recurring revenue +9% reported, +7% organic.
- Record quarterly instrument placements including nearly 2,400 IDEXX inVue Dx units.
- FY2025 revenue guidance raised to $4,205M-$4,280M (prior $4,095M-$4,210M); organic growth outlook 7.0%-9.0%.
- FY2025 EPS guidance raised to $12.40-$12.76 (prior $11.93-$12.43); reported growth 16%-20%.
- Operating margin guidance improved to 31.3%-31.6%; comparable expansion 50-80 bps.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874716/000110465925073304/0001104659-25-073304-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874716/000110465925073304/tm2522386d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-073304

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer